Jaguar Health, Inc. JAGX

JAGX Company Overview

Jaguar Health, Inc. is a U.S.-based commercial-stage pharmaceuticals and plant-based therapeutics company focused on developing and commercializing prescription medicines derived from sustainably harvested rainforest botanicals. The company primarily operates in the gastrointestinal health and supportive care markets, with an emphasis on treatments for chronic and debilitating diarrhea conditions in both human and animal health applications. Jaguar Health’s principal commercial product is crofelemer, marketed under the brand name Mytesi, which is approved in the United States for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also pursues additional indications for crofelemer involving rare diseases, cancer therapy-related diarrhea, and inflammatory gastrointestinal disorders.

The company traces its origins to Jaguar Animal Health, founded in 2013 by entrepreneur and executive Lisa A. Conte, before evolving into Jaguar Health through public market transactions and strategic restructuring. Jaguar expanded beyond veterinary applications into human pharmaceuticals through the acquisition and integration of Napo Pharmaceuticals, Inc., which became a core operating subsidiary and intellectual property holder for crofelemer-related assets. Jaguar Health positions itself through a differentiated strategy centered on botanical drug development, orphan and supportive care indications, and proprietary plant-derived formulations supported by regulatory pathways established under U.S. FDA botanical drug guidance.